ClinicalTrials.gg
RecruitingNCT00902447Updated Nov 20, 2026

Human Blood Cell Disorders Tissue Bank

An observational study in Human Blood Cell Disorders and Lymphoid, Myeloid and Erythroid Proliferative Disease, sponsored by Northwell Health. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Northwell Health · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
10,000
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The Human Blood Cell Disorder Tissue Bank will provide a convenient, comprehensive source of tissue containing populations of human blood cells from patients with various types of lymphoid, myeloid, and erythroid proliferative diseases as well as other associated conditions. The tissue bank will continue to be an invaluable asset for understanding of the biology of multiple blood cell disorders involving several cell types as well as the physiology of normal cellular counterparts affected in these disorders. Internal and external investigators will be able to utilize this tissue to test hypotheses relating to the immunologic, virologic, genetic, and molecular properties of these abnormal cells as well as normal cells from normal unaffected family members or normal aged matched subjects to provide better comparisons.

02

Conditions studied

  • Human Blood Cell Disorders
  • Lymphoid, Myeloid and Erythroid Proliferative Disease

Keywords

  • Human Blood Cell Disorders
  • lymphoid, myeloid and erythroid proliferative disease
03

In context

Lead sponsor

Northwell Health is the lead sponsor of 476 studies on the registry; 106 are open to participants now.

Of its 48 completed or terminated interventional studies of FDA-regulated products, 23 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Community sample

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants or participant's Legally Authorized Representatives (LAR) must be able to understand and render voluntary, written .
  • Patients must be able to contribute the required amount of blood and/or tissue without compromising their well-being or care.
  • Participants must be willing to be contacted again for consideration of additional studies in the future, such as a blood draw or another action (e.g., bone marrow aspiration and/or ) that would be done as part of their standard of care.

Exclusion criteria

Exclusion Criteria:

  • Patients who are known to be anemic, with \<8.0g/dl.
  • Patients who are known to be infected with .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
10,000 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Human Blood Cell Disorders

    Human Blood Cell Disorders Tissue Bank

06

What researchers measure

Primary outcomes

  1. Accumulate tissue from patients with various blood disorders, including but not restricted to lymphoproliferative, myeloproliferative, and erythroproliferative conditions.

    Time frame: Indefinite

Secondary outcomes

  1. Develop a database of at least 10,000 subjects who have donated samples for research as well as DNA banking, and who are willing to be contacted again for consideration of additional studies in the future.

    Time frame: Indefinite

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Jan 2030 and a completion of Jan 2035. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2009
First posted
May 15, 2009
Start
Apr 2009
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2035
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and contact details
1 update, last Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Minor edits only
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT00902447
Lead sponsor
Northwell Health
Responsible party
Sponsor
First posted
May 15, 2009
Start date
Apr 2009
Primary completion
Jan 2030 (estimated)
Completion
Jan 2035 (estimated)
Last update
Nov 20, 2026

Study contacts

Yasmine Kieso, MSCR
Contact
ykieso@northwell.edu
Nicholas Chiorazzi, M.D.
principal investigator · Northwell Health

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion